Welcome to Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialise innovative, first or best-in-class products for unmet medical needs in neurology and psychiatry. We utilise cutting edge technologies and creative clinical study designs to de-risk our compounds before moving into larger, more extensive Phase II and Phase III programmes. We currently have five clinical-stage compounds in development for neurological and psychiatric diseases that have high unmet medical need, including Parkinson’s disease and Alzheimer’s disease. For doctors, this means potential new treatment options for debilitating neurological conditions. For patients, it could mean vast improvements in quality of life.

Extending
the Reach
Download Company Brochure PDF
get the fast facts on Synosia

Learn More

Thomson Reuters
Synosia's nepicastat is 'one to watch'

BioBusiness Network 2007 Award Winner

Scrip Awards 2007 Finalist
Finalist for Licensing Deal of the Year

Email registration

Sign up for regular updates
on Synosia.

Synosia Therapeutics adopts a privacy policy and will not disclose your email address or details to any third party.